I am a healthcare professional

Notice


Welcome to MEDICALLY. This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals outside the United Kingdom (UK) and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Roche and Genentech do not support, endorse or recommend the unapproved use of any compound or service in your jurisdiction, including those discussed on this website.


Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same. Healthcare professionals outside the US are required to register and log-in to access the full range of content available on this website.


By clicking on one of the healthcare professional buttons below, you acknowledge you have read and understood this message and that you are requesting access to MEDICALLY. If you are not a healthcare professional, please use the other links below to access information relevant to you.


Cookies


We use cookies on this site to enable the site to function properly and to enhance your user experience. Cookies are files stored in your browser, which most websites use to personalize your web experience. Your information will only be used to provide information that is relevant to you. It will not be used for any other purpose. If you wish to restrict or block cookies, which are set on your device, then you can do this through your browser settings.


You can find out more about cookies by browsing our Privacy Policy.

 

For healthcare professionals in Another Country browse medically.roche.com.

Not a healthcare professional? For individuals outside the US, browse Roche's patient website or roche.com. For individuals in the US, browse gene.com.

External site

The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.

Leave site
Roche and Genentech at

AASLD Liver meeting 2024

We will be contributing to topics related to
-
03:00 PM
Duration 9hrs San Diago, CA
Outcomes of nucleos(t)ide analogue discontinuation following finite xalnesiran-based therapy in chronic hepatitis B: 48 week follow-up results from Piranga, a phase 2, randomized, controlled, adaptive, open-label platform study
Jinlin Hou, Qing Xie, Wenhong Zhang, Luis Enrique Morano Amado, Sheng-Shun Yang, Jidong Jia, Cheng-Yuan Peng, Wei-Wen Su, Jia-Horng Kao, Man-Fung Yuen, Tarik Asselah, Tawesak Tanwandee, Xieer Liang, Maria Teresa Catanese, Ethan Chen, Cong Cheng, Farouk Chughlay, Sudip Das, Katerina Glavini, Nelson Guerreiro, Yan Huang, Priyanka Kakrana, Rémi Kazma, Avinash Patil, Ruchi Upmanyu, Cynthia Wat, Edward Gane
Duration 9hrs San Diago, CA
Pharmacokinetic/pharmacodynamic modelling of RG6084 effects on hepatitis B surface antigen and alanine transaminase to inform Phase 2 dosing regimen selection
Sijie Lu, Sylvie Retout, Vedran Pavlovic, Greg Hooper, Gemma Attley, Annabelle Lemenuel-Diot
03:00 PM
Duration 9hrs San Diago, CA
Factors associated with type of first-line treatment received for unresectable hepatocellular carcinoma in the era of immunotherapy
Cheng S, To TM, Schuldt R, Tan A
03:00 PM
Duration 9hrs San Diago, CA
Efficacy and safety of xalnesiran in combination with the checkpoint inhibitor PD-L1 LNA in virologically suppressed participants with chronic hepatitis B: results from the Piranga phase 2, randomized, controlled, adaptive, open-label platform study
Karen Doucette, Deian Jelev, Jia-Horng Kao, Luis Enrique Morano Amado, Kosh Agarwal, Tarik Asselah, Anchalee Avihingsanon, Rozalina Balabanska, Wan-Long Chuang, Apinya Leerapun, Tien Huey Lim, Young-Suk Lim, Wei-Wen Su, Sheng-Shun Yang, Ed Gane, Gemma Attley, Maria Teresa Catanese, Farouk Chughlay, Anna Maria Geretti, Gregory Hooper, Rémi Kazma, Yukun Liang, Sijie Lu, Ruchi Upmanyu, Jeffrey Xu, Wen Zhang, Man-Fung Yuen
Duration 9hrs San Diago, CA
A novel mechanistic viral dynamics modeling (MVDM) framework to characterize and predict the effect of combination therapies in chronic hepatitis B: modeling of the Piranga phase 2, randomized, controlled, adaptive, open-label platform study
Annabelle Lemenuel-Diot, Selma El Messaoudi, Jeremie Guedj, Sylvie Retout, Franziska Schaedeli-Stark, Amine Ait-Ali, Nelson Guerreiro, Sijie Lu, Farouk Chughlay, Claire McGeown, Rémi Kazma
Coming soon